A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

{BOX}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

RSPCA WORMaway 230 mg/20 mg film-coated tablets

2. STATEMENT OF ACTIVE SUBSTANCES

Each film-coated tablet contains:
Active substances:

Pyrantel embonate	230 mg (equivalent to 80 mg pyrantel)
Praziquantel	20 mg

3. PACKAGE SIZE

2 tablets

4. TARGET SPECIES

Cats.

5. INDICATIONS

For the treatment of mixed infestations with roundworms, hookworms and tapeworms in cats.

6. ROUTES OF ADMINISTRATION

Read the package leaflet before use.
Oral use.
Dosage: 1 tablet per 4 kg body weight (5 mg praziquantel and 20 mg pyrantel base (57.5 mg pyrantel embonate) per kg of body weight), according to the table below:

Weight of cat	Tablets
1.0 - 2.0 kg	1/2
2.1 - 4.0 kg	1
4.1 - 6.0 kg	1 1/2
6.1 - 8.0 kg	2

7. WITHDRAWAL PERIOD

8. EXPIRY DATE

Exp. {mm/yyyy}
Shelf life of halved tablets after first opening the immediate packaging: 1 month.

9. SPECIAL STORAGE PRECAUTIONS

Store unused parts of the halved tablets below 25°C. Each time an unused part-tablet is stored until next use, it should be returned to the open blister pocket and kept in a safe place out of the sight and reach of children.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

User Warnings
In case of accidental ingestion, seek medical advice and show the package leaflet or the label to the physician. Wash hands after use. Keep the product in the outer package until ready to use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

KRKA, d.d., Novo mesto

14. MARKETING AUTHORISATION NUMBER

Vm 01656/5007
Vm 01656/3007

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

{BLISTER}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

RSPCA WORMaway

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

pyrantel embonate/prazinquantel
230 mg/20 mg

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

KRKA

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

RSPCA WORMaway 230 mg/20 mg film-coated tablets for cats

2. Composition

Each film-coated tablet contains:
Active substances:

Pyrantel embonate	230 mg (equivalent to 80 mg pyrantel)
Praziquantel	20 mg

White to almost white, biconvex, oval film-coated tablet, scored on one side. The tablet can be divided into halves.

3. Target species

Cats.

4. Indications for use

For the treatment of mixed infestations with roundworms, hookworms and tapeworms in cats, caused by:

- adult stages of roundworms: *Toxocara cati (syn. mystax)*
- adult stages of hookworms: *Ancylostoma tubaeforme, Ancylostoma braziliense*
- tapeworms*: Echinococcus multilocularis, Dipylidium caninum, Hydatigera (Taenia) taeniaeformis, Mesocestoides spp., Joyeuxiella pasqualei.*

Roundworms and tapeworms are parasites that live in the gut. If left untreated they can cause your cat to become unwell. Treating these infestations will reduce the risk of other animals and humans being exposed to worm infections.

5. Contraindications

Do not use simultaneously with products containing piperazine as piperazine may block the action of pyrantel embonate contained in the product. Other worming products may contain piperazine.
Do not use simultaneously with other deworming products without veterinary advice.
Do not use in kittens less than 6 weeks of age,
Do not use in animals known to be allergic to the active substances (pyrantel embonate and praziquantel) or to any of the other ingredients (excipients).
Do not use during pregnancy.

6. Special warnings

Special warnings for each target species:
Tapeworm infestation occurs in cats at the earliest in the third week of life.
Fleas serve as intermediate hosts for one common type of tapeworm – *Dipylidium caninum*.
Tapeworm infestation is certain to reoccur unless control of intermediate hosts such as fleas, mice, etc.is undertaken.
Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:
- Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.
- Underdosing, this may be due to underestimation of body weight or misadministration of the product.
Do not use in cats less than 6 weeks of age or weighing less than 1 kg bodyweight.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
In case of accidental ingestion, seek medical advice and show the package leaflet or the label to the physician.
In the interest of good hygiene, persons administering the tablets directly to the cat or by adding them to the cat's food, should wash their hands afterwards.

Other precautions:
Echinococcosis represents a hazard for humans. As Echinococcosis is a notifiable disease to the World Organisation for Animal Health (WOAH), it must be reported to your veterinary surgeon, as specific guidelines on the treatment and follow-up, and on the safeguard of persons, need to be obtained from the relevant competent authority.

Pregnancy:
The safety of the veterinary medicinal product has not been established during pregnancy.
Do not use during pregnancy.

Lactation:
Can be used during lactation.

Interaction with other medicinal products and other forms of interaction:
Do not use simultaneously with piperazine compounds, because the specific activities of piperazine (neuromuscular paralysis of the parasites) can inhibit the efficacy of pyrantel (spastic paralysis of the parasites). Do not use simultaneously with any other deworming products. If your cat receives other veterinary medicinal products, check with a veterinary surgeon or pharmacist before using this product.

Overdose (symptoms, emergency procedures, antidotes):
Symptoms of overdoses do not occur at less than 5 times the recommended dose.
The first expected sign of intoxication is vomiting.

Incompatibilities:
Not applicable.

7. Adverse events

Cats:

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Digestive tract disorders (e.g. hypersalivation and/or vomiting)* Neurological disorders (e.g. ataxia)*

*Mild and transient.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or its local representative using the contact details at the end of this leaflet, or via your national reporting system at:
Website: https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine
e-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes and method of administration

Dosage:
5 mg praziquantel and 20 mg pyrantel base (57.5 mg pyrantel embonate) per kg of body weight. This corresponds to 1 tablet per 4 kg of body weight, according to the table below:

Weight of cat	Tablets
1.0 - 2.0 kg	1/2
2.1 - 4.0 kg	1
4.1 - 6.0 kg	1 1/2
6.1 - 8.0 kg	2

Kittens weighing less than 1 kg should not be treated with the product, because correct dosing of such cats may not be feasible.

Route of administration:
Oral use.
The tablets are to be given directly into the mouth but can be administered in a small amount of food, if necessary.

Duration of use:
Single treatment

In ascarid infestation, especially in kittens, complete elimination cannot be expected, so a risk of infection for humans can persist. Repeat treatments should therefore be carried out with a suitable roundworm product at 14 day intervals until 2-3 weeks after weaning.

If signs of disease persist or appear, consult a veterinary surgeon.

9. Advice on correct administration

To ensure administration of a correct dose, body weight should be determined as accurately as possible.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

Store unused parts of the halved tablets below 25°C.
Each time an unused part-tablet is stored until next use, it should be returned to the open blister pocket and kept in a safe place out of the sight and reach of children.
Shelf life of halved tablets after first opening the immediate packaging: 1 month.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton after Exp. The expiry date refers to the last day of that month.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product not subject to prescription.

14. Marketing authorisation numbers and pack sizes

Vm 01656/5007
Vm 01656/3007

Box with 1 blister of 2 tablets.

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder:
KRKA, d.d., Novo mesto
Šmarješka cesta 6
8501 Novo mesto
Slovenia

Manufacturer responsible for batch release:
KRKA - FARMA d.o.o., V. Holjevca 20/E, 10450 Jastrebarsko, Croatia
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia

Local representatives and contact details to report suspected adverse reactions:
KRKA UK Ltd
United Kingdom
Tel: 02071 646 156
info.uk@krka.biz

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

17. Other information

AVM-GSL

Gavin Hall
Approved: 12 June 2026